Over the past decade, multiple monoclonal antibodies, blocking either PD-(L)1 or CTLA-4, have been evaluated in many randomized phase III clinical trials and were able to show significant survival benefit with favorable toxicity profiles in patients with NSCLC. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.